23 July 2019

By Dr Wendy Winnall - PCFA Research Team

Apalutamide improves survival times in men with metastatic prostate cancer when used with hormone therapy.

Apalutamide (Erlyand) is a new drug that delays disease progression in men with advanced prostate cancer whose PSA is rising despite hormone therapy. Apalutamide has now been tested as a treatment at an earlier stage of advanced prostate cancer. This week’s blog describes exciting new results from the TITAN clinical trial.

To read the full article just log into the PCFA Online Community.

If you're not already a member, it is free and easy to join.

Join Online Community Button